2026-06-14T03:42:41Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/141642025-04-29T09:48:18Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16963col_20.500.12105_16978col_20.500.12105_16988

00925njm 22002777a 4500 dc Díez, Cristina author Del Romero-Raposo, Jorge author Micán, Rafael author López, Juan C author Blanco, José Ramón author Calzado, Sonia author Samperiz, Gloria author Portilla, Joaquín author García-Fraile, Lucio Jesús author Gutiérrez, Félix author Gómez-Sirvent, Juan L author Suárez-García, Inés author Amador, Concha author Novella, María author Arribas, José R author Moreno, Santiago author González-García, Juan author Jarrin Vera, Inmaculada author Berenguer, Juan author CoRIS Cohort author 2021-10 Objectives: We compared the characteristics and clinical outcomes of hospitalized individuals with COVID-19 with [people with HIV (PWH)] and without (non-PWH) HIV co-infection in Spain during the first wave of the pandemic. Methods: This was a retrospective matched cohort study. People with HIV were identified by reviewing clinical records and laboratory registries of 10 922 patients in active-follow-up within the Spanish HIV Research Network (CoRIS) up to 30 June 2020. Each hospitalized PWH was matched with five non-PWH of the same age and sex randomly selected from COVID-19@Spain, a multicentre cohort of 4035 patients hospitalized with confirmed COVID-19. The main outcome was all-cause in-hospital mortality. Results: Forty-five PWH with PCR-confirmed COVID-19 were identified in CoRIS, 21 of whom were hospitalized. A total of 105 age/sex-matched controls were selected from the COVID-19@Spain cohort. The median age in both groups was 53 (Q1-Q3, 46-56) years, and 90.5% were men. In PWH, 19.1% were injecting drug users, 95.2% were on antiretroviral therapy, 94.4% had HIV-RNA < 50 copies/mL, and the median (Q1-Q3) CD4 count was 595 (349-798) cells/μL. No statistically significant differences were found between PWH and non-PWH in number of comorbidities, presenting signs and symptoms, laboratory parameters, radiology findings and severity scores on admission. Corticosteroids were administered to 33.3% and 27.4% of PWH and non-PWH, respectively (P = 0.580). Deaths during admission were documented in two (9.5%) PWH and 12 (11.4%) non-PWH (P = 0.800). Conclusions: Our findings suggest that well-controlled HIV infection does not modify the clinical presentation or worsen clinical outcomes of COVID-19 hospitalization. HIV Medicine. 2021 Oct;22(9):867-876. 10.1111/hiv.13145 1468-1293 HIV Medicine 34324783 http://hdl.handle.net/20.500.12105/14164 COVID-19 Coronavirus HIV SARS-CoV-2 COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study